Literature DB >> 19847846

Synthesis, inhibition potency, binding mode, and antiprotozoal activities of fluorescent inhibitors of trypanothione reductase based on mepacrine-conjugated diaryl sulfide scaffolds.

Christian Eberle1, Johannes A Burkhard, Bernhard Stump, Marcel Kaiser, Reto Brun, R Luise Krauth-Siegel, François Diederich.   

Abstract

Trypanothione reductase (TR) is a flavoenzyme unique to trypanosomatid parasites and a target for lead discovery programs. Various inhibitor scaffolds have emerged in the past, exhibiting moderate affinity for the parasite enzyme. Herein we show that the combination of two structural motifs of known TR inhibitors - diaryl sulfides and mepacrine - enables the simultaneous addressing of two hydrophobic patches in the active site. The binding efficacy of these conjugates is enhanced over that of the respective parent inhibitors. They show K(ic) values for the parasite enzyme down to 0.9+/-0.1 microm and exhibit high selectivity for TR over human glutathione reductase (GR). Despite their considerable molecular mass and in some cases permanent positive charges, in vitro studies revealed IC(50) values in the low micromolar to sub-micromolar range against Trypanosoma brucei rhodesiense and Trypanosoma cruzi, as well as the malaria parasite Plasmodium falciparum, which lack trypanothione metabolism. The inhibitors exhibit strong fluorescence due to their aminoacridine moiety. This feature allows visualization of the drugs in the parasite where high accumulation was observed by fluorescence microscopy even after short exposure times.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19847846     DOI: 10.1002/cmdc.200900327

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  6 in total

1.  Huprines as a new family of dual acting trypanocidal-antiplasmodial agents.

Authors:  Julien Defaux; Marta Sala; Xavier Formosa; Carles Galdeano; Martin C Taylor; Waleed A A Alobaid; John M Kelly; Colin W Wright; Pelayo Camps; Diego Muñoz-Torrero
Journal:  Bioorg Med Chem       Date:  2011-01-21       Impact factor: 3.641

2.  Novel Heteroaryl Selenocyanates and Diselenides as Potent Antileishmanial Agents.

Authors:  Ylenia Baquedano; Verónica Alcolea; Miguel Ángel Toro; Killian Jesús Gutiérrez; Paul Nguewa; María Font; Esther Moreno; Socorro Espuelas; Antonio Jiménez-Ruiz; Juan Antonio Palop; Daniel Plano; Carmen Sanmartín
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

3.  Dihydroquinazolines as a novel class of Trypanosoma brucei trypanothione reductase inhibitors: discovery, synthesis, and characterization of their binding mode by protein crystallography.

Authors:  Stephen Patterson; Magnus S Alphey; Deuan C Jones; Emma J Shanks; Ian P Street; Julie A Frearson; Paul G Wyatt; Ian H Gilbert; Alan H Fairlamb
Journal:  J Med Chem       Date:  2011-09-01       Impact factor: 7.446

4.  Quantitative Structure-Activity Relationships for Structurally Diverse Chemotypes Having Anti-Trypanosoma cruzi Activity.

Authors:  Anacleto S de Souza; Leonardo L G Ferreira; Aldo S de Oliveira; Adriano D Andricopulo
Journal:  Int J Mol Sci       Date:  2019-06-08       Impact factor: 5.923

Review 5.  Targeting Trypanothione Reductase, a Key Enzyme in the Redox Trypanosomatid Metabolism, to Develop New Drugs against Leishmaniasis and Trypanosomiases.

Authors:  Theo Battista; Gianni Colotti; Andrea Ilari; Annarita Fiorillo
Journal:  Molecules       Date:  2020-04-21       Impact factor: 4.411

Review 6.  Synthetic Medicinal Chemistry in Chagas' Disease: Compounds at The Final Stage of "Hit-To-Lead" Phase.

Authors:  Hugo Cerecetto; Mercedes González
Journal:  Pharmaceuticals (Basel)       Date:  2010-03-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.